The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Adavosertib in combination with carboplatin in advanced TP53-mutated platinum-resistant ovarian cancer.
 
Alaa Embaby
No Relationships to Disclose
 
Jill Jacqueline Geenen
No Relationships to Disclose
 
Joachim Kutzera
No Relationships to Disclose
 
Dick Pluim
No Relationships to Disclose
 
Marta I. Lopez-Yurda
No Relationships to Disclose
 
Jos H. Beijnen
Employment - Modra Pharmaceuticals
Stock and Other Ownership Interests - Modra Pharmaceuticals
Honoraria - Modra Pharmaceuticals
Research Funding - Modra Pharmaceuticals (Inst); Neon Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Patent dealing with the pharmaceutical formulation of oral taxanes (Inst)
Expert Testimony - Hoyng Rokh Monegier (Inst)
 
Alwin Huitema
Research Funding - Merus NV (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
 
Petronella Witteveen
No Relationships to Disclose
 
Neeltje Steeghs
Consulting or Advisory Role - AIMM Therapeutics (Inst); Boehringer Ingelheim (Inst); Ellipses Pharma (Inst)
Research Funding - Abbvie (Inst); Actuate Therapeutics (Inst); Amgen (Inst); Array BioPharma (Inst); Ascendis Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); BridgeBio Pharma (Inst); Bristol-Myers Squibb (Inst); Cantargia AB (Inst); Celgene (Inst); CellCentric (Inst); Crescendo Biologics (Inst); Cytovation (Inst); Deciphera (Inst); Exelixis (Inst); Genentech (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); InteRNA (Inst); Janssen (Inst); Kinnate Biopharma (Inst); Lilly (Inst); Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Merus (Inst); Molecular Partners (Inst); Novartis (Inst); Numab (Inst); Pfizer (Inst); Pierre Fabre (Inst); Regeneron (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); SERVIER (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Gijs van Haaften
No Relationships to Disclose
 
Marcel A.T.M. van Vugt
Consulting or Advisory Role - Repare Therapeutics
 
Jeroen de Ridder
Patents, Royalties, Other Intellectual Property - N.A.
Other Relationship - Cyclomics BV
 
Frans Opdam
(OPTIONAL) Uncompensated Relationships - AstraZeneca/Merck (Inst); Boehringer Ingelheim (Inst); Cytovation (Inst); GlaxoSmithKline (Inst); InteRNA (Inst); Merus NV (Inst); Pierre Fabre (Inst); Taiho Oncology (Inst)